Treating Heart Failure With Enhanced External Counterpulsation (EECP)
NCT ID: NCT03021213
Last Updated: 2018-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2017-01-31
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Effects of EECP in Patients With Heart Failure
NCT03857022
Long-tErm Effects of Enhanced eXternal CountErpuLsation
NCT05913778
HARapan kiTa ECP (External Counter Pulsation) Study HARTEC Study
NCT03991871
High-intensity Interval Training in Heart Failure Patients With Preserved Ejection Fraction
NCT03184311
Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection Fraction
NCT07270536
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. with optimal medical therapy
2. caused by ischemic or non-ischemic cardiomyopathy
* EECP-Therapy and Treatment in the Cardio Centrum Berlin or Charité - University Medicine Berlin
* Aged 18 to 100 years
* Offered patient information and written informed consent
Exclusion Criteria
* Acute coronary syndrome \< 4 weeks prior to enrollment
* Operation \< 4 weeks prior to enrollment
* Stroke \< 4 weeks prior to enrollment
* Clinically significant disease with hospitalization
* Aortic valvular heart disease ≥ moderate
* Aortic aneurysm
* clinically relevant severe cardiopulmonal diseases
* Resting RR \> 160/90mmHg
* Thrombose, Thrombophlebitis \< 8 weeks prior to enrollment
* Peripheral artery occlusive disease ≥ Stadium II
* Acute Heart failure
* Pathological bleeding tendency
* Arrhythmias, which interfere with Triggering of the EECP
* Other diseases, that inhibit EECP-Treatment (e.g. Spinal disc herniation)
* Accommodation in an institution due to an official or judicial order
* Women: pregnancy or lactation
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Charite University, Berlin, Germany
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Claudia Spies
Head of the Department of Anesthesiology and Intensive Care Medicine CVK/CCM, Campus Virchow - Klinikum, Charité - University Medicine Berlin
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Claudia Spies, MD, Prof.
Role: STUDY_DIRECTOR
Charite University, Berlin, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Anesthesiology and Intensive Care Medicine CVK/CCM, Charité - University Medicine Berlin
Berlin, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EECP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.